Literature DB >> 27538406

Genetic and epigenetic cancer chemoprevention on molecular targets during multistage carcinogenesis.

Hyung Sik Kim1, Sam Kacew2, Byung Mu Lee3.   

Abstract

The main goal of cancer chemoprevention is to prevent or halt the progression of carcinogenesis with the administration of synthetic or natural compounds. Fundamental chemopreventive strategies include inhibition of genetic damage, anti-proliferation/cell cycle regulation, and induction of apoptosis and anti-inflammatory processes, which may be critical for carcinogenesis intervention. Recently, a new paradigm for identifying chemopreventive agents has been implemented. It focuses on defining new biomarkers that can be used to evaluate chemopreventive efficacy based on multistage carcinogenesis. The functional roles of chemopreventive agents are associated with the modulation of nuclear factor kappa B, nuclear factor erythroid 2-related factor, p53, AMPK/mTOR, phosphatidylinositol 3-kinase, epidermal growth factor receptor, cyclooxygenase-2, chemokine (C-X-C motif) receptor 2, and sphingosine-1-phosphate. This paper summarizes the genetic and epigenetic effects of chemopreventive agents on the expression of cancer-related target genes mediated by epigenetic alterations, such as DNA methylation and histone modifications. This review will provide unique and effective strategies for reducing cancer and aging-related diseases in humans.

Entities:  

Keywords:  Biomarkers; Chemoprevention; Epigenetic; Genetic; Inflammation; Multistage

Mesh:

Substances:

Year:  2016        PMID: 27538406     DOI: 10.1007/s00204-016-1813-9

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  1 in total

1.  Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells.

Authors:  Han Han; Jing Li; Xiuyan Feng; Hui Zhou; Shanchun Guo; Weiqiang Zhou
Journal:  Oncotarget       Date:  2017-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.